Fluticasone propionate - Adare Pharmaceuticals

Drug Profile

Fluticasone propionate - Adare Pharmaceuticals

Alternative Names: APT 1011; EUR 1100

Latest Information Update: 27 Jun 2017

Price : $50

At a glance

  • Originator Aptalis
  • Developer Adare Pharmaceuticals
  • Class Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophagitis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Eosinophilic oesophagitis

Most Recent Events

  • 16 Jun 2017 Phase-II clinical trials in Eosinophilic oesophagitis in USA (PO) (NCT03191864)
  • 02 Apr 2015 Aptalis Pharmaceuticals has been acquired by TGP and renamed Adare Pharmaceuticals
  • 03 Feb 2014 Aptalis has been acquired by Forest Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top